AstraZeneca AB Deal History & Licensing Activity
AstraZeneca AB is a large pharma headquartered in UK. Over the past three years, AstraZeneca AB has been involved in 5 licensing and acquisition transactions, with a primary focus on Small Molecules (4 deals). The company currently has 1 active clinical trial, primarily in Oncology.
Deals (12mo)
4
Active Trials
1
Top Modality
Small Molecules
Focus Area
Oncology
AstraZeneca AB Recent Deal Activity
Licensing, acquisition, and partnership transactions involving AstraZeneca AB in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| EGFR degrader | AstraZeneca | Small Molecules | Unknown | license | Apr 30, 2026 |
| EGFR degrader | AstraZeneca | Small Molecules | Unknown | acquisition | Apr 30, 2026 |
| Enhertu (trastuzumab deruxtecan) | AstraZeneca | ADC | Approved | collaboration |
AstraZeneca AB Pipeline Focus
Therapeutic areas and modalities where AstraZeneca AB is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
AstraZeneca AB Strategic Signals
Key indicators of AstraZeneca AB's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
AstraZeneca AB Clinical Pipeline
AstraZeneca AB has 1 active clinical trial across 1 development phase.
1
Phase 1
See How Your Asset Matches AstraZeneca AB's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Women's Health Deal Benchmarks
Market sizing, deal terms, and competitive landscape for women's health
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About AstraZeneca AB Licensing & Deal Activity
AstraZeneca AB is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, AstraZeneca AB ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for AstraZeneca AB include Oncology (2 deals and trials), Other (2 deals and trials), Women's Health (2 deals and trials), and Rare Disease (2 deals and trials). In terms of modality, AstraZeneca AB has shown particular interest in small molecules, adc, peptides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for AstraZeneca AB and 850+ other biopharma companies. Use our Solidus to benchmark your asset against AstraZeneca AB's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.